

**Preliminary Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-32 (canceled)

Claim 33 (currently amended): A method of identifying an optimal range of zeta potential for a composition for targeting to ~~a specific site~~ an activated vascular site comprising evaluating zeta potential ~~for~~ of the composition for vascular endothelial cell uptake, wherein the composition is associated with different amounts of a cationic component that targets the composition to the activated vascular site, and identifying an optimal range of zeta potential.

Claim 34-36 (canceled)

Claim 37 (currently amended): An imaging composition for selective targeting to an activated vascular site comprising an imaging agent obtained by the method of claim 36 ~~58~~ and a carrier.

Claim 38 (withdrawn): The imaging composition of claim 37, wherein the imaging agent is selected from the group consisting of iron oxide particles, dyes, fluorescent dyes, NMR labels, scintigraphic labels, gold particles, PET labels, ultrasound contrast media, and CT contrast media.

Claim 39 (withdrawn): The imaging composition of claim 37, wherein the composition comprises particles having a zeta potential in the range of about +25 mV to +60 mV in about 0.05 mM KCl solution at about pH 7.5.

Claim 40 (withdrawn): The imaging composition of claim 39, wherein the composition comprises particles having a zeta potential in the range of about +30 to +50 mV in about 0.05 mM KCl solution at about pH 7.5.

Claim 41 (currently amended): A therapeutic composition for selective targeting to an activated vascular site comprising a therapeutically effective amount of an agent obtained by the method of claim ~~36~~ 58 and a carrier.

Claim 42 (withdrawn): The therapeutic composition of claim 41, wherein the agent is selected from the group consisting of cytostatics and cytotoxic agents.

Claim 43 (withdrawn): The therapeutic composition of claim 42, wherein the cytostatics and cytotoxic agents are selected from the group consisting of taxanes, inorganic complexes, mitose inhibitors, hormones, anthracyclines, antibodies, topoisomerase inhibitors, antiinflammatory agents, alkaloids, interleukins, cytokines, growth factors, proteins, peptides, and tetracyclines.

Claim 44 (withdrawn): The therapeutic composition of claim 41, wherein the agent is selected from the group consisting of etherlipid, alkyllysolecithin, alkyllysophospholipid, lysolipid, alkylphospholipid.

Claim 45 (withdrawn): The therapeutic composition of claim 44, wherein the etherlipid is selected from the group consisting of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, 1-O-Hexadecyl-2-O-methyl-sn-glycerol, Hexadecyl phosphocholine, Octadecylphosphocholine.

Claim 46 (withdrawn): The therapeutic composition of claim 41, wherein the composition comprises particles having a zeta potential in the range of about +25 mV to +60 mV in about 0.05 mM KCl solution at about pH 7.5.

Claim 47 (withdrawn): The composition of claim 46, wherein the composition comprises particles having a zeta potential in the range of about +30 to +50 mV in about 0.05 mM KCl solution at about pH 7.5.

Claim 48 (currently amended): A therapeutic composition effective for the treatment of an angiogenesis associated disease comprising an agent obtained by the method of claim 36 58 and a carrier, wherein the composition further being labeled or packaged with directions for the administration of the composition to treat an angiogenesis associated disease.

Claim 49 (currently amended): A therapeutic composition effective to inhibit inflammation comprising an agent obtained by the method of claim 36 58 and a carrier, wherein the composition further being labeled or packaged with directions for the administration of the composition to inhibit inflammation.

Claim 50 (currently amended): A therapeutic composition effective to promote bone repair or wound healing, comprising an agent obtained by the method of claim 36 58 and a carrier, wherein the composition further being labeled or packaged with directions for the administration of the composition to promote bone repair or wound healing.

Claim 51 (currently amended): A diagnostic composition effective for diagnosis or imaging of an angiogenesis associated disease comprising an active agent obtained by the method of claim 36 58 and a carrier, wherein the composition further being labeled or packaged with directions for the administration of the composition to diagnose or image an angiogenesis

associated disease.

Claim 52 (canceled)

Claim 53 (new): A method of claim 33 wherein the cationic component is selected from the group consisting of:

- (a) particles;
- (b) liposomes comprising cationic lipids in the range of about 25 mol% to about 50 mol%; and
- (c) oil-in-water emulsions or microemulsions comprising cationic amphiphiles characterized by comprising two fatty acid chains or alkyl chains in the outer layer in the range of about 25 mol% to 60 mol%.

Claim 54 (new): A method of claim 53, wherein the a zeta potential is measured in about 0.05 mM KCl solution at about pH 7.5

Claim 55 (new): A method of claim 33, wherein the cationic component comprises molecules having an isoelectric point above 7.5.

Claim 56 (new): A method of claim 33, wherein the cationic component comprises magnetosomes with a cationic lipid layer.

Claim 57 (new): A method of claim 56, wherein the zeta potential is measured in about 0.05 mM KCl solution at about pH 7.5.

Claim 58 (new): A method of modifying an agent to enhance its efficacy comprising associating the agent with one or more cationic components to produce a composition having an optimal range of zeta potential for specific targeting to an activated vascular site, wherein the cationic components target the composition to the activated vascular site, and wherein the

composition has a zeta potential in the range of about +30 mV to +65 mV in about 0.05 mM KCl solution at about pH 7.5.

Claim 59 (new): A method of claim 58, wherein the cationic components are selected from the group consisting of :

- (a) particles;
- (b) liposomes comprising cationic lipids in the range of about 25 mol% to about 50 mol%; and
- (c) oil-in-water emulsions or microemulsions comprising cationic amphiphiles characterized by comprising two fatty acid chains or alkyl chains in the outer layer in the range of about 25 mol% to 60 mol%.

Claim 60 (new): A method of modifying an agent to enhance its efficacy comprising associating the agent with one or more cationic components to produce a composition having an optimal range of zeta potential for specific targeting to an activated vascular site, wherein the cationic components comprise molecules having an isoelectric point above 7.5 and target the composition to the activated vascular site, and wherein the composition has an isoelectric point above 7.5.

Claim 61 (new): A method of modifying an agent to enhance its efficacy comprising associating the agent with one or more cationic components to produce a composition having an optimal range of zeta potential for specific targeting to an activated vascular site, wherein the cationic components comprise magnetosomes with a cationic lipid layer and target the composition to the activated vascular site, and wherein the composition has a zeta potential in the range of about +25 to +100 mV in about 0.05 mM KCl solution at about pH 7.5.

Claim 62 (new): A method of claims 33, wherein the composition comprises an agent selected from the group consisting of imaging agent, therapeutic agent, and diagnostic agent.

Claim 63 (new): A method of any one of claims 58, 60, or 61, wherein the agent is selected from the group consisting of imaging agent, therapeutic agent, and diagnostic agent.

Claim 64 (new): A method of claim 62, wherein the imaging agent is selected from the group consisting of iron oxide particles, dyes, fluorescent dyes, NMR labels, scintigraphic labels, gold particles, PET labels, ultrasound contrast media, and CT contrast media.

Claim 65 (new): A method of claim 63, wherein the imaging agent is selected from the group consisting of iron oxide particles, dyes, fluorescent dyes, NMR labels, scintigraphic labels, gold particles, PET labels, ultrasound contrast media, and CT contrast media.

Claim 66 (new): A method of claim 62, wherein the therapeutic agent is selected from the group consisting of cytostatic agent and cytotoxic agents.

Claim 67 (new): A method of claim 63, wherein the therapeutic agent is selected from the group consisting of cytostatic agent and cytotoxic agents.

Claim 68 (new): A method of claim 66, wherein the cytostatic agent or cytotoxic agent is selected from the group consisting of taxanes, inorganic complexes, mitose inhibitors, hormones, anthracyclines, antibodies, topoisomerase inhibitors, anti-inflammatory agents, alkaloids, interleukins, cytokines, growth factors, proteins, peptides, and tetracyclines.

Claim 69 (new): A method of claim 67, wherein the cytostatic agent or cytotoxic agent is selected from the group consisting of taxanes, inorganic complexes, mitose inhibitors, hormones, anthracyclines, antibodies, topoisomerase inhibitors, anti-inflammatory agents, alkaloids, interleukins, cytokines, growth factors, proteins, peptides, and tetracyclines.

Claim 70 (new): A method of claim 62, wherein the therapeutic agent is selected from the group consisting of etherlipid, alkyllysolecithin, alkyllysophospholipid, lysolipid, and alkylphospholipid.

Claim 71 (new): A method of claim 63, wherein the therapeutic agent is selected from the group consisting of etherlipid, alkyllysolecithin, alkyllysophospholipid, lysolipid, and alkylphospholipid.

Claim 72 (new): A method of claim 70, wherein the etherlipid is selected from the group consisting of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, 1-O-Hexadecyl-2-O-methyl-sn-glycerol, Hexadecyl phosphocholine, and Octadecylphosphocholine.

Claim 73 (new): A method of claim 71, wherein the etherlipid is selected from the group consisting of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, 1-O-Hexadecyl-2-O-methyl-sn-glycerol, Hexadecyl phosphocholine, and Octadecylphosphocholine.

Claim 74 (new): A method of claim 58, wherein the cationic components are selected from the group consisting of DOTAP, DOPE, DOPC, iron oxide particles, and dextran.